



Ebola

Ebola is a disease caused by the Ebola virus. This virus supposedly introduces itself in the human population through close contact with animals. An American company holds the Ebola virus patent. The patent number is “No. CA2741523 A1,” issued in 2010.

Human ebola virus species and compositions and methods thereof

CA 2741523 A1

RESUMEN

Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.

DESCRIPCIÓN (El texto procesado por OCR puede contener errores)

HUMAN EBOLA VIRUS SPECIES AND COMPOSITIONS AND METHODS THEREOF

DEPOSIT STATEMENT

[001] The invention provides the isolated human Ebola (hEbola) viruses denoted as Bundibugyo (EboBun) deposited with the Centers for Disease Control and Prevention (“CDC”, Atlanta, Georgia, United States of America) on November 26, 2007 and accorded an accession number 200706291. This deposit was not made to an International Depository Authority (IDA) as established under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, and is a non-Budapest treaty deposit. The deposited organism is not acceptable by American Type Culture Collection (ATCC), Manassas, Virginia, an International Depository Authority (IDA) as established under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. Samples of the stated Deposit Accession No. 200706291 will be made available to approved facilities for thirty years from the date of deposit, and for the lifetime of the patent issuing from, or claiming priority to this application.

Número de publicación CA2741523 A1
 Tipo de publicación Solicitud
 Número de solicitud CA 2741523
 Número de PCT PCT/US2009/082079
 Fecha de publicación 29 Abr 2010
 Fecha de presentación 26 Oct 2009
 Fecha de prioridad 24 Oct 2008

También publicado como EP2350270A2, 5 más »
 Inventores Jonathan S. Towner, 4 más »
 Solicitante Jonathan S. Towner, 5 más »
 Exportar cita BiTeX, EndNote, RefMan
 Clasificaciones (29), Eventos legales (1)

Enlaces externos: Oficina de propiedad intelectual de Canadá, Espacenet

RECLAMACIONES (30)

1. An isolated hEbola virus comprising a nucleic acid molecule comprising a nucleotide sequence of:
 - a) a nucleotide sequence set forth in SEQ ID NOS: 1 or 10;
 - b) a nucleotide sequence hybridizing under stringent conditions to SEQ ID NOS: 1 or 10; or c) a nucleotide sequence of at least 70%-99% identity to the SEQ ID NOS: 1 or 10.
2. An isolated hEbola virus having Centers for Disease Control Deposit Accession No. 200706291.
3. The hEbola virus of any one of claims 1 or 2 which is killed.
4. The hEbola virus of claim 1 which is an attenuated hEbola virus.
5. The virus of claim 4 wherein at least one property of the attenuated hEbola virus is reduced from among infectivity, replication ability, protein synthesis ability, assembling ability or cytopathic effect.
6. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ

Fig. 39: Patent No. CA 2741523 A1 referring to Ebola virus

Symptoms

Typically, symptoms start to manifest between two days and three weeks after contracting the virus. The infected individuals are not contagious until they start showing symptoms such as fever, sore throat, muscle pain, headaches, vomiting, diarrhea, skin rash, renal and hepatic failure, and in some cases, internal and external hemorrhages.

Testimonial

There is an extensive website that publishes successful treatment results.
Mutsuro Ishii

Fuente: <http://mmsjapan.sharepoint.com/Pages/ebola.aspx>

Author's note: I want to acknowledge and thank Mutsuro Ishii for his courageous work in Ebola pandemic areas, where he traveled without concern for his own life and of his own initiative, with excellent results.

Editor's comment: The above link no longer works. The following link does work:

<https://www.facebook.com/ebola.np/posts/possibility-of-treatment-and-prevention-for-ebola-my-name-is-mutsurou-ishii-i-am-/692758494142403/>

Treatment

Appropriate treatment, for this case, would be using Protocol F (frequent) followed by ~~Protocol B (basic)~~ or Protocol C (CDS). In clinical cases, Protocol Y (injection) should be used when there is no improvement with the others.